

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

April 21, 2026

To,
BSE Limited
Phiroze Jeejeebhoy
Towers Dalal Street
Mumbai - 400 001

Dear Sir / Ma'am,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited ("the Company") has acquired equity shares of "Cohance Lifesciences Limited". The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Para A of Part A of Schedule III of the SEBI Listing Regulations, is attached as "Annexure A".

This is for your information and record.

Thanking you,

For **Elpro International Limited**

DEEPAK
KUMAR
AJMERA

Digitally signed by
DEEPAK KUMAR
AJMERA
Date: 2026.04.21
18:00:08 +05'30'

Deepak Kumar Ajmera
Chief Financial Officer

Encl. as above

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

Annexure A

| Sr. No. | Particulars | Details | | | | | | | | |
|-------------------------|--|---|-------------|--------------------|-------------------------|----------|--------------|-------|--------------|-----------------|
| 1. | Name of the target entity, details in brief such as size, turnover etc.: | Name of the target entity: Cohance Lifesciences Limited Consolidated Turnover as per last audited financials (FY 2024-25): <table border="1"><thead><tr><th>Particulars</th><th>Amount (in Crores)</th></tr></thead><tbody><tr><td>Revenue from Operations</td><td>1,197.58</td></tr><tr><td>Other income</td><td>58.56</td></tr><tr><td>Total</td><td>1,256.14</td></tr></tbody></table> | Particulars | Amount (in Crores) | Revenue from Operations | 1,197.58 | Other income | 58.56 | Total | 1,256.14 |
| Particulars | Amount (in Crores) | | | | | | | | | |
| Revenue from Operations | 1,197.58 | | | | | | | | | |
| Other income | 58.56 | | | | | | | | | |
| Total | 1,256.14 | | | | | | | | | |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length": | No | | | | | | | | |
| 3. | Industry to which the entity being acquired belongs: | Pharmaceuticals | | | | | | | | |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity): | Investment Purpose | | | | | | | | |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition: | N.A. | | | | | | | | |
| 6. | Indicative time period for completion of the acquisition: | N.A. | | | | | | | | |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same: | Cash consideration | | | | | | | | |

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

| 8. | Cost of acquisition or the price at which the shares are acquired: | INR 4.79 Crores | | | | | | | | | | | | | | | | | | | |
|-------------------------|---|---|-----------------|--------------------|--|--|------------|------------|------------|-------------------------|----------|----------|----------|--------------|-------|-------|-------|--------------|-----------------|-----------------|-----------------|
| 9. | Percentage of shareholding / control acquired and/or number of shares acquired: | Fresh Acquisition: 1,33,086 Equity Shares (Previous Holding: 1,15,727 Equity Shares) (Total Holding with Fresh Acquisition: 2,48,813 Equity Shares) | | | | | | | | | | | | | | | | | | | |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief): | <p>Brief Background:</p> <p>Cohance Lifesciences is a culmination of vision, scientific ambition, and purposeful integration. Their story began with a series of intentional moves, starting with the acquisition of RA Chem Pharma. Over time, a deliberate series of mergers and acquisitions—including ZCL Chemicals, Avra Laboratories, Suven Pharmaceuticals, Sapala Organics, and NJ Bio—brought together differentiated capabilities in Pharma CDMO, APIs, Specialty Chemicals, Formulations and next-gen platforms.</p> <p>Line of Business:</p> <p>Pharmaceuticals</p> <p>Website of the entity:</p> <p>www.cohance.com</p> <p>Date of Incorporation:</p> <p>06/11/2018</p> <p>Consolidated Turnover of last 3 Financial Years:</p> <table border="1"><thead><tr><th rowspan="2">Particulars</th><th colspan="3">Amount (in Crores)</th></tr><tr><th>FY 2024-25</th><th>FY 2023-24</th><th>FY 2022-23</th></tr></thead><tbody><tr><td>Revenue from Operations</td><td>1,197.58</td><td>1,051.35</td><td>1,340.33</td></tr><tr><td>Other income</td><td>58.56</td><td>61.91</td><td>46.36</td></tr><tr><td>Total</td><td>1,256.14</td><td>1,113.26</td><td>1,386.69</td></tr></tbody></table> <p>Country in which the target has presence:</p> <p>India and United States of America</p> | Particulars | Amount (in Crores) | | | FY 2024-25 | FY 2023-24 | FY 2022-23 | Revenue from Operations | 1,197.58 | 1,051.35 | 1,340.33 | Other income | 58.56 | 61.91 | 46.36 | Total | 1,256.14 | 1,113.26 | 1,386.69 |
| Particulars | Amount (in Crores) | | | | | | | | | | | | | | | | | | | | |
| | FY 2024-25 | FY 2023-24 | FY 2022-23 | | | | | | | | | | | | | | | | | | |
| Revenue from Operations | 1,197.58 | 1,051.35 | 1,340.33 | | | | | | | | | | | | | | | | | | |
| Other income | 58.56 | 61.91 | 46.36 | | | | | | | | | | | | | | | | | | |
| Total | 1,256.14 | 1,113.26 | 1,386.69 | | | | | | | | | | | | | | | | | | |